|
|
Article: Swiss Firm GlycoVaxyn Raises $9.5M For Vaccine Programs.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Seed investors in GlycoVaxyn AG returned to provide CHF11.5 million (US$9.5 million) in a Series A financing, money that will be used in development of conjugated vaccines against bacterial infections.
Schlieren, Switzerland-based GlycoVaxyn said its technology is able to simplify the production process of conjugated vaccines, offering advantages in terms of costs and in addressing novel targets.
Urs Tuor, head of corporate development and a company co-founder, told BioWorld Today the two seed investors from a year ago gained confidence in the technology after seeing proof of concept in animal models. He said the Series A financing ...
Related newspaper, magazine, and journal articles:
|
|
Article: Reporting Period? January 02?March 02: Enforcement Policy & ...
Mondaq Business Briefing;
May 22, 2002 ;
700+ words
... ... Competition Act. On November 7, 2001 the Swiss Federal Council submitted for parliamentary ... In its report on the draft law, the Swiss Federal Council reiterated the opinion according ... Amendments. Unlike the initial draft, the Swiss Federal Council has given up modifying the ...
|
|